Chapter 4.5 The endocannabinoid system and anxiety responses

Handbook of Behavioral Neuroscience

Volumn 17, Issue , 2008, Pages 303-324

  Bortolato, Marco ^a   Piomelli, Daniele ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b 3101 Gillespie Neuroscience Facility   (United States)

Author keywords

2 AG; anandamide; anxiety; CB; endocannabinoids; receptor; rimonabant; URB597

Indexed keywords

EID: 67649736168     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-7339(07)00014-8     Document Type: Review

References (207)

1. Adamec R.E. Transmitter systems involved in neural plasticity underlying increased anxiety and defense - implications for understanding anxiety following traumatic stress. Neurosci. Biobehav. Rev. 21 (1997) 755-765
2. Adams R., Loewe S., Jelinek C., and Wolff H. Tetrahydrocannabinol homologs with marihuana activity. J. Am. Chem. Soc. 63 (1941) 1-1973
3. Akinshola B.E., Chakrabarti A., and Onaivi E.S. In-vitro and in-vivo action of cannabinoids. Neurochem. Res. 24 (1999) 1233-1240
4. Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 58 (1999) 315-348
5. Arevalo C., De Miguel R., and Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav. 70 (2001) 123-131
6. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., and Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325 (2002) 1212-1213
7. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., Liu J., and Kunos G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106 (2005) 133-145
8. Beinfeld M.C., and Connolly K. Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci. Lett. 301 (2001) 69-71
9. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
10. Belzung C. Rodent models of anxiety-like behaviors: are they predictive for compounds acting via non-benzodiazepine mechanisms?. Curr. Opin. Investig. Drugs 2 (2001) 1108-1111
11. Berrendero F., and Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by delta(9)-tetrahydrocannabinol. Psychopharmacology 163 (2002) 111-117
12. Bhattacharya S.K., Chakrabarti A., Sandler M., and Glover V. Effects of some anxiogenic agents on rat brain monoamine oxidase (MAO) A and B inhibitory (tribulin) activity. Indian J. Exp. Biol. 34 (1996) 1190-1193
13. Bickerdike M.J., Marsden C.A., Dourish C.T., and Fletcher A. The influence of 5- hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur. J. Pharmacol. 271 (1994) 403-411
14. Biro E., Toth G., and Telegdy G. Involvement of neurotransmitters in the 'anxiolytic-like' action of atrial natriuretic peptide in rats. Neuropeptides 29 (1995) 215-220
15. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., Matias I., Schiano-Moriello A., Paul P., Williams E.J., Gangadharan U., Hobbs C., Di Marzo V., and Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163 (2003) 463-468
16. Bortolato M., Campolongo P., Mangieri R.A., Scattoni M.L., Frau R., Trezza V., La Rana G., Russo R., Calignano A., Gessa G.L., Cuomo V., and Piomelli D. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31 (2006) 2652-2659
17. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry 62 (2007) 1103-1110
18. Bradshaw H.B., and Walker J.M. The expanding field of cannabimimetic and related lipid mediators. Br. J. Pharmacol. 144 (2005) 459-465
19. Braida D., Limonta V., Malabarba L., Zani A., and Sala M. 5-HT(1A) receptors are involved in the anxiolytic effect of Delta(9)-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur. J. Pharmacol. 555 (2007) 156-163
20. Breivogel C.S., Griffin G., Di Marzo V., and Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60 (2001) 155-163
21. Cadas H., di Tomaso E., and Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17 (1997) 1226-1242
22. Cahill L., and McGaugh J.L. Mechanisms of emotional arousal and lasting declarative memory. Trends Neurosci. 21 (1998) 294-299
23. Celerier E., Ahdepil T., Wikander H., Berrendero F., Nyberg F., and Maldonado R. Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence. Neuropharmacology 50 (2006) 788-806
24. Chang L., Luo L., Palmer J.A., Sutton S., Wilson S.J., Barbier A.J., Breitenbucher J.G., Chaplan S.R., and Webb M. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br. J. Pharmacol. 148 (2006) 102-113
25. Chaperon F., and Thiebot M.H. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13 (1999) 243-281
26. Charney D.S., and Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit. Rev. Neurobiol. 10 (1996) 419-446
27. Charrier D., Dangoumau L., Puech A.J., Hamon M., and Thiebot M.H. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology 121 (1995) 127-134
28. Chhatwal J.P., Davis M., Maguschak K.A., and Ressler K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30 (2005) 516-524
29. Chopin P., and Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 110 (1993) 409-414
30. Conti L.H., Costello D.G., Martin L.A., White M.F., and Abreu M.E. Mouse strain differences in the behavioral effects of corticotropin-releasing factor (CRF) and the CRF antagonist alpha-helical CRF9-41. Pharmacol. Biochem. Behav. 48 (1994) 497-503
31. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
32. Dannon P.N., Lowengrub K., Amiaz R., Grunhaus L., and Kotler M. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum. Psychopharmacol. 19 (2004) 97-101
33. Davidson E.S., and Schenk S. Variability in subjective responses to marijuana: initial experiences of college students. Addict. Behav. 19 (1994) 531-538
34. Davis M., Rainnie D., and Cassell M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci. 17 (1994) 208-214
35. Dawson G.R., Rupniak N.M., Iversen S.D., Curnow R., Tye S., Stanhope K.J., and Tricklebank M.D. Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology 121 (1995) 109-117
36. De Lago E., Fernandez-Ruiz J., Ortega-Gutierrez S., Viso A., Lopez-Rodriguez M.L., and Ramos J.A. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur. J. Pharmacol. 449 (2002) 99-103
37. Degenhardt L., Hall W., and Lynskey M. The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. Soc. Psychiatry Psychiatr. Epidemiol. 36 (2001) 219-227
38. Degroot A., and Nomikos G.G. Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur. J. Neurosci. 20 (2004) 1059-1064
39. Deiana S., Fattore L., Spano M.S., Cossu G., Porcu E., Fadda P., and Fratta W. Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology 52 (2006) 646-654
40. Desarnaud F., Cadas H., and Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J. Biol. Chem. 270 (1995) 6030-6035
41. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34 (1988) 605-613
42. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
43. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., and Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994) 686-691
44. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., and Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 99 (2002) 10819-10824
45. Dinh T.P., Freund T.F., and Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids 121 (2002) 149-158
46. Durham, R.A., Li, W., Bhattacharya, K., Kinsora, J., Snyder, B., Lotarski, S., Sadagopan, N., Johnson, D.S. and Ahn, K. (2006) Inhibition of fatty acid amide hydrolase: the search for an anxiolytic or antidepressant indication. Program No. 830.3. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.
47. Fabre L.F., and McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J. Clin. Pharmacol. 21 (1981) 377S-382S
48. Fadda P., Robinson L., Fratta W., Pertwee R.G., and Riedel G. Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47 (2004) 1170-1179
49. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313 (2004) 352-358
50. Fergusson D.M., Horwood L.J., and Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97 (2002) 1123-1135
51. File S.E. Behavioural detection of anxiolytic action. In: Elliot J.M., Heal D.J., and Marsden C.A. (Eds). Experimental Approaches to Anxiety and Depression (1992), Wiley, New York 25-44
52. Fowler C.J. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends Pharmacol. Sci. 25 (2004) 59-61
53. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 (2003) 1017-1066
54. Gaoni Y., and Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86 (1964) 1646
55. Gatley S.J., Gifford A.N., Volkow N.D., Lan R., and Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 307 (1996) 331-338
56. Gatley S.J., Lan R., Pyatt B., Gifford A.N., Volkow N.D., and Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 61 (1997) 191-197
57. Gelfand E.V., and Cannon C.P. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin. Invest. Drugs 15 (2006) 307-315
58. Genn R.F., Tucci S., Marco E.M., Viveros M.P., and File S.E. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol. Biochem. Behav. 77 (2004) 567-573
59. Gerdeman G.L., Ronesi J., and Lovinger D.M. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5 (2002) 446-451
60. Ghozland S., Matthes H.W., Simonin F., Filliol D., Kieffer B.L., and Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J. Neurosci. 22 (2002) 1146-1154
61. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkotter J., and Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29 (2004) 2108-2114
62. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., and Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2 (1999) 358-363
63. Giuliani D., Ferrari F., and Ottani A. The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol. Res. 41 (2000) 47-53
64. Glass M., Faull R.L.M., and Dragunow M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study on the fetal, neonatal and adult human brain. Neuroscience 77 (1997) 299-318
65. Glass R.M., Uhlenhuth E.H., Hartel F.W., Schuster C.R., and Fischman M.W. A single dose study of nabilone, a synthetic cannabinoid. Psychopharmacology 71 (1980) 137-142
66. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., and Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA 102 (2005) 18620-18625
67. Gonzalez L.E., Andrews N., and File S.E. 5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain. Res. 732 (1996) 145-153
68. Grant B.F., and Pickering R. The relationship between cannabis use and DSM-IV cannabis abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J. Subst. Abuse 10 (1998) 255-264
69. Green B., Kavanagh D., and Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 22 (2003) 453-460
70. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65 (1995) 319-395
71. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?. Pharmacol. Ther. 82 (1999) 1-61
72. Griebel G., Perrault G., and Sanger D.J. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology 138 (1998) 55-66
73. Griebel G., Stemmelin J., and Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57 (2005) 261-267
74. Hajos N., and Freund T.F. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43 (2002) 503-510
75. Hall W., and Solowij N. Adverse effects of cannabis. Lancet 352 (1998) 1611-1616
76. Haller J., Bakos N., Szirmay M., Ledent C., and Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16 (2002) 1395-1398
77. Haller J., Varga B., Ledent C., and Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol. 15 (2004) 299-304
78. Haney M. The marijuana withdrawal syndrome: diagnosis and treatment. Curr. Psychiatry Rep. 7 (2005) 360-366
79. Heilig M., McLeod S., Koob G.K., and Britton K.T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul. Pept. 41 (1992) 61-69
80. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., and van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330 (2005) 11
81. Henquet C., Murray R., Linszen D., and van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 31 (2005) 608-612
82. Herkenham M., Groen B.G., Lynn A.B., De Costa B.R., and Richfield E.K. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res. 552 (1991) 301-310
83. Herkenham M., Lynn A.B., de Costa B.R., and Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547 (1991) 267-274
84. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 (1991) 563-583
85. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice KC. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 87 (1990) 1932-1936
86. Hill M.N., and Gorzalka B.B. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol. 499 (2004) 291-295
87. Hillard C.J., Edgemond W.S., Jarrahian A., and Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69 (1997) 631-638
88. Hillard C.J., and Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol. 140 (2003) 802-808
89. Hillard C.J., Wilkison D.M., Edgemond W.S., and Campbell W.B. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochem. Biophys. Acta 1257 (1995) 249-256
90. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., Krey J.F., Walker J.M., Holmes P.V., Crystal. J.D., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature 435 (2005) 1108-1112
91. Hollister L.E. Health aspects of cannabis. Pharmacol. Rev. 38 (1986) 1-20
92. Holt S., Comelli F., Costa B., and Fowler C.J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol. 146 (2005) 467-476
93. Hopfer C.J., Young S.E., Purcell S., Crowley T.J., Stallings M.C., Corley R.P., Rhee S.H., Smolen A., Krauter K., Hewitt J.K., and Ehringer M.A. Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141 (2006) 895-901
94. Howlett A.C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 68-69 (2002) 619-631
95. Ilaria R.L., Thornby J.I., and Fann W.E. Nabilone, a cannabinol derivative, in the treatment of anxiety neurosis. Curr. Ther. Res. 29 (1981) 943-949
96. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., and Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA 96 (1999) 14136-14141
97. Jarbe T.U., DiPatrizio N.V., Lu D., and Makriyannis A. (-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. Behav. Pharmacol. 15 (2004) 517-521
98. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., and Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147 (2006) 281-288
99. Jhaveri M.D., Richardson D., Kendall D.A., Barrett D.A., and Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J. Neurosci. 26 (2006) 13318-13327
100. Jung K.M., Mangieri R., Stapleton C., Kim J., Fegley D., Wallace M., Mackie K., and Piomelli D. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol. Pharmacol. 68 (2005) 1196-1202
101. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., and Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9 (2003) 76-81
102. Katona I., Rancz E.A., Acsady L., Ledent C., Mackie K., Hajos N., and Freund TF. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 21 (2001) 9506-9518
103. Kim J., and Alger B.E. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat. Neurosci. 7 (2004) 697-698
104. Kim M., and McGaugh J.L. Effects of intra-amygdala injections of NMDA receptor antagonists on acquisition and retention of inhibitory avoidance. Brain Res. 585 (1992) 35-48
105. Koenen K.C., Lyons M.J., Goldberg J., Simpson J., Williams W.M., Toomey R., Eisen S.A., True W., and Tsuang M.T. Co-twin control study of relationships among combat exposure, combat-related PTSD, and other mental disorders. J. Trauma Stress 16 (2003) 433-438
106. Koob G.F., Sanna P.P., and Bloom F.E. Neuroscience of addiction. Neuron 21 (1998) 467-476
107. Kozak K.R., and Marnett L.J. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 211-220
108. Kozak K.R., Prusakiewicz J.J., and Marnett L.J. Oxidative metabolism of endocannabinoids by COX-2. Curr. Pharm. Des. 10 (2004) 659-667
109. LeDoux J.E. Emotion, memory and the brain. Sci. Am. 270 (1994) 50-57
110. Lichtman A.H., Leung D., Shelton C.C., Saghatelian A., Hardouin C., Boger D.L., and Cravatt B.F. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311 (2004) 441-448
111. Lichtman A.H., Shelton C.C., Advani T., and Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109 (2004) 319-327
112. Liu J., Wang L., Harvey-White J., Osei-Hyiaman D., Razdan R., Gong Q., Chan A.C., Zhou Z., Huang B.X., Kim H.Y., and Kunos G. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci., USA 103 (2006) 13345-13350
113. Maccarrone M., Bari M., Battista N., and Finazzi-Agro A. Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood 100 (2002) 4040-4048
114. Maccarrone M., Bari M., and Finazzi-Agro A. Quantification of anandamide content in animal cells and tissues: the normalization makes the difference. Lipids Health Dis. 1 (2002) 4
115. Maccarrone M., Del Principe D., and Finazzi-Agro A. Endocannabinoids: new physiological (co-) agonists of human platelets. Thromb. Haemost. 88 (2002) 165-166
116. Maccarrone M., Falciglia K., Di Rienzo M., and Finazzi-Agro A. Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 309-317
117. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 168 (2005) 299-325
118. Makara J.K., Mor M., Fegley D., Szabo S.I., Kathuria S., Astarita G., Duranti A., Tontini A., Tarzia G., Rivara S., Freund T.F., and Piomelli D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat. Neurosci. 8 (2005) 1139-1141
119. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20 (1999) 287-294
120. Marco E.M., Granstrem O., Moreno E., Llorente R., Adriani W., Laviola G., and Viveros M.P. Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB(1) and mu-opioid receptors in rats. Eur. J. Pharmacol. 172 (2006) 46-53
121. Marco E.M., Perez-Alvarez L., Borcel E., Rubio M., Guaza C., Ambrosio E., File S.E., and Viveros M.P. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol. 15 (2004) 21-27
122. Maren S. Synaptic transmission and plasticity in the amygdala, an emerging physiology of fear conditioning circuits. Mol. Neurobiol. 13 (1996) 1-22
123. Marin S., Marco E., Biscaia M., Fernandez B., Rubio M., Guaza C., Schmidhammer H., and Viveros M.P. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol. Biochem. Behav. 74 (2003) 649-656
124. Marsicano G., Moosmann B., Hermann H., Lutz B., and Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80 (2002) 448-456
125. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgansberger W., Di Marzo V., and Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
126. Martin M., Ledent C., Parmentier M., Maldonado R., and Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159 (2002) 379-387
127. Matsuda L.A., Bonner T.I., and Lolait S.J. Cannabinoid receptors: which cells, where, how, and why?. NIDA Res. Monogr. 126 (1992) 48-56
128. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
129. McGregor C., Darke S., Ali R., and Christie P. Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction 93 (1998) 701-711
130. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., and Compton D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995) 83-90
131. Menzaghi F., Heinrichs S.C., Merlo-Pich E., Tilders F.J., and Koob G.F. Involvement of hypothalamic corticotropin-releasing factor neurons in behavioral responses to novelty in rats. Neurosci. Lett. 168 (1994) 139-142
132. Menzaghi F., Howard R.L., Heinrichs S.C., Vale W., Rivier J., and Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp. Ther. 269 (1994) 564-572
133. Menzaghi F., Rassnick S., Heinrichs S., Baldwin H., Pich E.M., Weiss F., and Koob G.F. The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann. N.Y. Acad. Sci. 739 (1994) 176-184
134. Mikics E., Dombi T., Barsvari B., Varga B., Ledent C., Freund T.F., and Haller J. The effects of cannabinoids on contextual conditioned fear in CB1 knockout and CD1 mice. Behav. Pharmacol. 17 (2006) 223-230
135. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70 (2003) 83-244
136. Milani R.M., Parrott A.C., Turner J.J., and Fox H.C. Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addict. Behav. 29 (2004) 965-971
137. Miserendino M.J., Sananes C.B., Melia K.R., and Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 345 (1990) 716-718
138. Mokler D.J., Robinson S.E., Johnson J.H., Hong J.S., and Rosecrans J.A. Effects of postweaning administration of delta-9-tetrahydrocannabinol (THC) on adult behavioral and neuroendocrine function in Sprague-Dawley and Fischer-344 rats. Neurobehav. Toxicol. Teratol. 8 (1986) 407-413
139. Morishita W., and Alger B.E. Evidence for endogenous excitatory amino acids as mediators in DSI of GABA(A)ergic transmission in hippocampal CA1. J. Neurophysiol. 82 (1999) 2556-2564
140. Morley K.C., Li K.M., Hunt G.E., Mallet P.E., and McGregor I.S. Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats. Neuropharmacology 46 (2004) 954-965
141. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
142. Navarro M., Hernandez E., Munoz R.M., del Arco I., Villanua M.A., Carrera M.R., and Rodriguez de Fonseca F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8 (1997) 491-496
143. Nemeroff C.B. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol. Bull. 37 (2003) 133-146
144. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., Hen R., Koester S., Lederhendler I., Meaney M., Robbins T., Winsky L., and Zalcman S. Preclinical models: status of basic research in depression. Biol. Psychiatry 52 (2002) 503-528
145. O'Shea M., McGregor I.S., and Mallet P.E. Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. Psychopharmacology 20 (2006) 611-621
146. O'Shea M., Singh M.E., McGregor I.S., and Mallet P.E. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J. Psychopharmacol. 18 (2004) 502-508
147. O'Sullivan S.E., Kendall D.A., and Randall M.D. Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br. J. Pharmacol. 142 (2004) 435-442
148. Ohno-Shosaku T., Maejima T., and Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29 (2001) 729-738
149. Okamoto Y., Morishita J., Tsuboi K., Tonai T., and Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279 (2004) 5298-5305
150. Okulate G.T., and Jones O.B. Post-traumatic stress disorder, survivor guilt and substance use--a study of hospitalised Nigerian army veterans. S. Afr. Med. J. 96 (2006) 144-146
151. Onaivi E.S., Green M.R., and Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther. 253 (1990) 1002-1009
152. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58 (2006) 389-462
153. Parker L.A., and Gillies T. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav. Neurosci. 109 (1995) 71-78
154. Patel S., Cravatt B.F., and Hillard C.J. Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 30 (2005) 497-507
155. Patel S., and Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther. 318 (2006) 304-311
156. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., and Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145 (2004) 5431-5438
157. Patel S., Roelke C.T., Rademacher D.J., and Hillard C.J. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur. J. Neurosci. 21 (2005) 1057-1069
158. Patton G.C., Coffey C., Carlin J.B., Degenhardt L., Lynskey M., and Hall W. Cannabis use and mental health in young people: cohort study. BMJ 325 (2002) 1195-1198
159. Pertwee R. The evidence for the existence of cannabinoid receptors. Gen. Pharmacol. 24 (1993) 811-824
160. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4 (2003) 873-884
161. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr. Opin. Investig. Drugs 6 (2005) 672-679
162. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., and Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA 96 (1999) 5802-5807
163. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., and Putman D. Pharmacological profile of the selective FAAH inhibitor DS-4103 (URB597). CNS Drug Rev. 12 (2006) 21-38
164. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J., and RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
165. Ramos A., and Mormede P. Stress and emotionality: a multidimensional and genetic approach. Neurosci. Biobehav. Rev. 22 (1998) 33-57
166. Rey J.M., Sawyer M.G., Raphael B., Patton G.C., and Lynskey M. Mental health of teenagers who use cannabis. Results of an Australian survey. Br. J. Psychiatry 180 (2002) 216-221
167. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., and Caput D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
168. Robbe D., Alonso G., Chaumont S., Bockaert J., and Manzoni O.J. Role of p/q-Ca2+ channels in metabotropic glutamate receptor 2/3-dependent presynaptic long-term depression at nucleus accumbens synapses. J. Neurosci. 22 (2002) 4346-4356
169. Robbe D., Bockaert J., and Manzoni O.J. Metabotropic glutamate receptor 2/3-dependent long-term depression in the nucleus accumbens is blocked in morphine withdrawn mice. Eur. J. Neurosci. 16 (2002) 2231-2235
170. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry 178 (2005) 107-115
171. Rodgers R.J. Animal models of 'anxiety': where next?. Behav. Pharmacol. 8 (1997) 477-496
172. Rodgers R.J., Evans P.M., and Murphy A. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav. Pharmacol. 16 (2005) 405-413
173. Rodgers R.J., Haller J., Halasz J., and Mikics E. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci. 17 (2003) 1279-1286
174. Rodriguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., and Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276 (1997) 2050-2054
175. Rodriguez de Fonseca F., Rubio P., Menzaghi F., Merlo-Pich E., Rivier J., Koob G.F., and Navarro M. Corticotropin-releasing factor (CRF) antagonist [d-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 276 (1996) 56-64
176. Romero E.M., Fernandez B., Sagredo O., Gomez N., Uriguen L., Guaza C., De Miguel R., Ramos J.A., and Viveros M.P. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Brain Res. Dev. Brain. Res. 136 (2002) 85-92
177. Rutkowska M., Jamontt J., and Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol. Rep. 58 (2006) 200-206
178. Saario S.M., Savinainen J.R., Laitinen J.T., Jarvinen T., and Niemi R. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem. Pharmacol. 67 (2004) 1381-1387
179. Sajdyk T.J., and Shekhar A. Excitatory amino acid receptor antagonists block the cardiovascular and anxiety responses elicited by gamma-aminobutyric acid A receptor blockade in the basolateral amygdala of rats. J. Pharmacol. Exp. Ther. 283 (1997) 969-977
180. Schlicker E., Timm J., Zentner J., and Gothert M. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedebergs Arch. Pharmacol. 356 (1998) 583-589
181. Schneider M., Drews E., and Koch M. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2. Behav. Pharmacol. 16 (2005) 447-454
182. Selden N.R., Everitt B.J., and Robbins T.W. Telencephalic but not diencephalic noradrenaline depletion enhances behavioural but not endocrine measures of fear conditioning to contextual stimuli. Behav. Brain Res. 43 (1991) 139-154
183. Shepard J.D., Barron K.W., and Myers D.A. Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior. Brain Res. 861 (2000) 288-295
184. Sjögren S., Ryberg E., Lindblom A., Larsson N., Åstrand A., Hjorth S., Andersson A., Groblewski T., and Greasley P. A new receptor for cannabinoid ligands. Symposium on the Cannabinoids (2005), International Cannabinoid Research Society, Burlington, VT
185. Sjostrom P.J., Turrigiano G.G., and Nelson S.B. Neocortical LTD via coincident activation of presynaptic NMDA and cannabinoid receptors. Neuron 39 (2003) 641-654
186. Stark-Adamec C., Adamec R.E., and Pihl R.O. The subjective marijuana experience: great expectations. Int. J. Addict. 16 (1981) 1169-1181
187. Stein D.J., Westenberg H.G., and Liebowitz M.R. Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J. Clin. Psychiatry 63 (2002) 12-19
188. Stella N., Schweitzer P., and Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997) 773-778
189. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215 (1995) 89-97
190. Sun Y.X., Tsuboi K., Okamoto Y., Tonai T., Murakami M., Kudo I., and Ueda N. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem. J. 380 (2004) 749-756
191. Swift W., Gates P., and Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct. J. 2 (2005) 18
192. Takahashi R.N., Pamplona F.A., and Fernandes M.S. The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci. Lett. 380 (2005) 270-275
193. Ueda N., Kurahashi Y., Yamamoto S., and Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J. Biol. Chem. 270 (1995) 23823-23827
194. Uriguen L., Perez-Rial. S., Ledent C., Palomo T., and Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46 (2004) 966-973
195. Valjent E., Mitchell J.M., Besson M.J., Caboche J., and Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol. 135 (2002) 564-578
196. Valverde O., Ledent C., Beslot F., Parmentier M., and Roques B.P. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur. J. Neurosci. 12 (2000) 533-539
197. Valverde O., Noble F., Beslot F., Dauge V., Fournie-Zaluski M.C., and Roques B.P. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur. J. Neurosci. 13 (2001) 1816-1824
198. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
199. Van Megen H.J., Westenberg H.G., den Boer J.A., and Kahn R.S. Cholecystokinin in anxiety. Eur. Neuropsychopharmacol. 6 (1996) 263-280
200. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., and Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
201. Varma N., Carlson G.C., Ledent C., and Alger B.E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21 (2001) RC188
202. Varvel S.A., Wise L.E., Niyuhire F., Cravatt B.F., and Lichtman A.H. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 32 (2007) 1032-1041
203. Weidenfeld J., Feldman S., and Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59 (1994) 110-122
204. Welch S.P., and Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 848 (1999) 183-190
205. Wilson R.I., and Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410 (2001) 588-592
206. Zimmer A., Valjent E., Konig M., Zimmer A.M., Robledo P., Hahn H., Valverde O., and Maldonado R. Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J. Neurosci. 21 (2001) 9499-9505
207. Zuardi A.W., Guimaraes F.S., and Moreira A.C. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz. J. Med. Biol. Res. 26 (1993) 213-217